A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer

Purpose This phase 1 study examined safety, pharmacokinetics (PK), and efficacy of the poly(ADP-ribose) polymerase (PARP) inhibitor ABT-767 in patients with advanced solid tumors and BRCA1/2 mutations or with high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. Methods Patients r...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Biessen, Diane A. J., Gietema, Jourik A., de Jonge, Maja J. A., Desar, Ingrid M. E., den Hollander, Martha W., Dudley, Matthew, Dunbar, Martin, Hetman, Robert, Serpenti, Camille, Xiong, Hao, Mittapalli, Rajendar K., Timms, Kirsten M., Ansell, Peter, Ratajczak, Christine K., Shepherd, Stacie Peacock, van Herpen, Carla M. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153550/
https://www.ncbi.nlm.nih.gov/pubmed/29313279
http://dx.doi.org/10.1007/s10637-017-0551-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153550/
https://www.ncbi.nlm.nih.gov/pubmed/29313279
http://dx.doi.org/10.1007/s10637-017-0551-z

Ejemplares similares